Selective PPAR-α activation with pemafibrate attenuates macrophage-mediated progression of calcific aortic valve disease
Mandy E Turner, Yuto Nakamura, Takeshi Tanaka, Mark C. Blaser, Taku Kasai, Adrien Lupieri, Shinsuke Itoh, Rile Ge, Katelyn A. Perez, Rei Itagawa, Luisa Weiß, Takehito Okui, Yusuke Sasaki, Aruna D. Pradhan, Peter Libby, , Elena Rabkin Aikawa
This study shows pemafibrate reduces calcific aortic valve disease by modulating macrophage-VIC interactions, independent of lipid lowering.
bioRxiv · Dec 19, 2025 · PreprintPharmacology & Toxicology